A Three-part, Multicenter, Open Label, Single Dose Study to Assess the Safety, Tolerability, and Efficacy of Intra Labyrinthine (IL) CGF166 in Patients With Severe-to-profound Hearing Loss

Trial Profile

A Three-part, Multicenter, Open Label, Single Dose Study to Assess the Safety, Tolerability, and Efficacy of Intra Labyrinthine (IL) CGF166 in Patients With Severe-to-profound Hearing Loss

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs CGF 166 (Primary)
  • Indications Hearing loss
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 14 Mar 2017 Planned End Date changed from 1 Aug 2017 to 12 Jun 2019.
    • 14 Mar 2017 Planned primary completion date changed from 1 Aug 2017 to 12 Jun 2019.
    • 05 Aug 2016 According to a GenVec media release, enrollment is underway in the fourth cohort.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top